Unique ID issued by UMIN | UMIN000005088 |
---|---|
Receipt number | R000006050 |
Scientific Title | A phase II trial of evaluating the benefit of zoledronic acid in non-small cell lung cancer patients with bone metastases and elevated marker of osteoclast activity. |
Date of disclosure of the study information | 2011/02/15 |
Last modified on | 2014/09/09 10:12:17 |
A phase II trial of evaluating the benefit of zoledronic acid in non-small cell lung cancer patients with bone metastases and elevated marker of osteoclast activity.
Benefit of zoledronic acid in non-small cell lung cancer patients with bone metastases.
A phase II trial of evaluating the benefit of zoledronic acid in non-small cell lung cancer patients with bone metastases and elevated marker of osteoclast activity.
Benefit of zoledronic acid in non-small cell lung cancer patients with bone metastases.
Japan |
Non-small cell lung cancer patients with bone metastases and elevated marker of osteoclast activity
Pneumology |
Malignancy
NO
To evaluate the efficacy of zoledronic acid in patients with NSCLC who has bone metastases with elevated urinary NTx. Primary endpoint: Proportion of patients who developed SRE.
Safety,Efficacy
Exploratory
Pragmatic
Phase II
Proportion of patients who developed SRE.
1.Time to first SRE 2.Safety 3.Progression free survival 4.Overall survival 5.Response rate 6.Rate of change of bone marker 7.Rate of change of pain score
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Zoledronic acid
20 | years-old | <= |
Not applicable |
Male and Female
Histologically or cytologically confirmed NSCLC.
Patients who have radiologically apparent bone metastasis.
Patients aged 20 years or older.
ECOG performance status of 0-2.
Sufficient function of main organ filled the following criteria before two weeks from enrollment:
Neu >= 1,500/ mm3
Hb >= 9.0g/dl
Plt >= 100,000/ mm3
T-Bil <= 1.5mg/dl
GOT <= 100IU/ml
GPT <= 100IU/ml
Cre <= 1.5mg/dl.
Urinary NTx> 64nmol/mmol Cr.
Written informed consent.
Patients who need radiotherapy or surgery immediately against bone metastases.
Prior treatment with Sr-89.
Prior bisphosphonates used for cancer.
Patients with symptomatic brain metastasis.
Severe odontopathy.
Interstitial pneumonia on chest x-ray.
Patients with active concomitant malignancy.
Uncontrolled heart disease, hepatic disease, diabetes mellitus, bleeding. EGFR (+) and planned for EGFR-TKI treatment.
55
1st name | |
Middle name | |
Last name | Koichi Takayama |
Kyushu University, Graduate School of Medical Sciences
Research Institute for Diseases of the Chest
3-1-1 Maidashi, higashi-ku, Fukuoka, Japan , 812-8582
092-642-5378
koichi-t@kokyu.med.kyushu-u.ac.jp
1st name | |
Middle name | |
Last name | Taishi Harada |
Kyushu University, Graduate School of Medical Sciences
Research Institute for Diseases of the Chest
3-1-1 Maidashi, higashi-ku, Fukuoka, Japan , 812-8582
092-642-5378
harada-t@kokyu.med.kyushu-u.ac.jp
Lung Oncology Group in Kyushu, Japan (LOGIK)
Clinical Research Support Center Kyushu
Non profit foundation
Japan
NO
飯塚病院(福岡県)
春回会 井上病院(長崎県)
大分県立病院大分県
大分大学大分県
沖縄県立南部医療センター・こども医療センター(沖縄県)
北九州市立医療センター(福岡県)
九州大学(福岡県)
九州大学(福岡県)
済生会福岡第二病院(福岡県)
佐賀県立病院好生館(佐賀県)
佐賀大学(佐賀県)
新別府病院大分県
川内市医師会立市民病院(鹿児島県)
長崎大学(長崎県)
浜の町病院(福岡県)
福岡大学(福岡県)
福岡大学(福岡県)
福岡大学 筑紫病院(福岡県)
国立病院機構 福岡東医療センター(福岡県)
国立病院機構大牟田病院(福岡県)
鹿児島大学(鹿児島県)
2011 | Year | 02 | Month | 15 | Day |
Unpublished
Open public recruiting
2010 | Year | 12 | Month | 10 | Day |
2010 | Year | 12 | Month | 01 | Day |
2014 | Year | 11 | Month | 30 | Day |
2011 | Year | 02 | Month | 15 | Day |
2014 | Year | 09 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006050